Seong-Jang Kim1,2,3, Sang-Woo Lee4, Hong Koo Ha5. 1. Department of Nuclear Medicine, Pusan National University Yangsan Hospital, Yangsan, Republic of Koreagrowthkim@daum.net. 2. BioMedical Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Republic of Koreagrowthkim@daum.net. 3. Department of Nuclear Medicine, College of Medicine, Pusan National University, Yangsan, Republic of Koreagrowthkim@daum.net. 4. Department of Nuclear Medicine, Kyungpook National University Medical Center and School of Medicine, Daegu, Republic of Korea. 5. Department of Urology, Pusan National University Hospital, Busan, Republic of Korea.
Abstract
INTRODUCTION: We aimed to assess the diagnostic accuracy of radiolabeled prostate-specific membrane antigen positron emission tomography (PSMA PET) or positron emission tomography/computed tomography (PET/CT) for primary lymph node (LN) staging in newly diagnosed intermediate to high-risk prostate cancer (PCa) patients. MATERIAL AND METHODS: The MEDLINE, PubMed, EMBASE, and Cochrane Library database from the earliest available date of indexing through May 31, 2018, were searched for studies evaluating the diagnostic performance of radiolabeled PSMA PET or PET/CT for primary LN staging in newly diagnosed intermediate to high-risk PCa. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR-), and constructed summary receiver operating characteristic curves. RESULTS: Across 6 studies (298 patients), the pooled sensitivity was 0.71 (95% CI 0.59-0.81) and a pooled specificity of 0.95 (95% CI 0.87-0.99). Likelihood ratio (LR) syntheses gave an overall positive likelihood ratio (LR+) of 15.6 (95% CI 5.6-43.0) and negative likelihood ratio (LR-) of 0.30 (95% CI 0.21-0.43). The pooled diagnostic odds ratio (DOR) was 51 (95% CI 21-126). CONCLUSION: Radiolabeled PSMA PET/CT shows a moderate sensitivity and high specificity for the detection of metastatic LNs in patients with newly diagnosed intermediate to high-risk PCa.
INTRODUCTION: We aimed to assess the diagnostic accuracy of radiolabeled prostate-specific membrane antigen positron emission tomography (PSMA PET) or positron emission tomography/computed tomography (PET/CT) for primary lymph node (LN) staging in newly diagnosed intermediate to high-risk prostate cancer (PCa) patients. MATERIAL AND METHODS: The MEDLINE, PubMed, EMBASE, and Cochrane Library database from the earliest available date of indexing through May 31, 2018, were searched for studies evaluating the diagnostic performance of radiolabeled PSMA PET or PET/CT for primary LN staging in newly diagnosed intermediate to high-risk PCa. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR-), and constructed summary receiver operating characteristic curves. RESULTS: Across 6 studies (298 patients), the pooled sensitivity was 0.71 (95% CI 0.59-0.81) and a pooled specificity of 0.95 (95% CI 0.87-0.99). Likelihood ratio (LR) syntheses gave an overall positive likelihood ratio (LR+) of 15.6 (95% CI 5.6-43.0) and negative likelihood ratio (LR-) of 0.30 (95% CI 0.21-0.43). The pooled diagnostic odds ratio (DOR) was 51 (95% CI 21-126). CONCLUSION: Radiolabeled PSMA PET/CT shows a moderate sensitivity and high specificity for the detection of metastatic LNs in patients with newly diagnosed intermediate to high-risk PCa.
Authors: Thomas A Hope; Jeremy Z Goodman; Isabel E Allen; Jeremie Calais; Wolfgang P Fendler; Peter R Carroll Journal: J Nucl Med Date: 2018-12-07 Impact factor: 10.057
Authors: Ida Sonni; Ely R Felker; Andrew T Lenis; Anthony E Sisk; Shadfar Bahri; Martin Allen-Auerbach; Wesley R Armstrong; Voraparee Suvannarerg; Teeravut Tubtawee; Tristan Grogan; David Elashoff; Matthias Eiber; Steven S Raman; Johannes Czernin; Robert E Reiter; Jeremie Calais Journal: J Nucl Med Date: 2021-10-14 Impact factor: 11.082
Authors: C M de Korne; E M Wit; J de Jong; R A Valdés Olmos; T Buckle; F W B van Leeuwen; H G van der Poel Journal: Eur J Nucl Med Mol Imaging Date: 2019-08-03 Impact factor: 9.236
Authors: Esther Mena; Peter C Black; Soroush Rais-Bahrami; Michael Gorin; Mohamad Allaf; Peter Choyke Journal: World J Urol Date: 2020-07-15 Impact factor: 4.226
Authors: Kelsey L Pomykala; Johannes Czernin; Tristan R Grogan; Wesley R Armstrong; John Williams; Jeremie Calais Journal: J Nucl Med Date: 2019-09-20 Impact factor: 11.082
Authors: Anthony Turpin; Edwina Girard; Clio Baillet; David Pasquier; Jonathan Olivier; Arnauld Villers; Philippe Puech; Nicolas Penel Journal: Front Oncol Date: 2020-01-31 Impact factor: 6.244